Molecular Regulation of Cardiac Inward Rectifier Potassium Channels by Pharmacologic Agents

Cardiac Electrophysiology: From Cell to Bedside: Sixth Edition

Volumn , Issue , 2014, Pages 129-137

  Sánchez Chapula, José A ^a   van der Heyden, Marcel A G ^b  

^a UNIVERSIDAD DE COLIMA   (Mexico)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940271113     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-2856-5.00013-3     Document Type: Chapter

References (59)

1. Katz B Les constants electriques de la membrane du muscle. Arch Sci Physiol 1949, 3:285-299.
2. Hibino H, Inanobe A, Furutani K, et al. Inwardly rectifying potassium channels: Their structure, function, and physiological roles. Physiol Rev 2010, 90:291-366.
3. Anumonwo JM, Lopatin AN Cardiac strong inward rectifier potassium channels. J Mol Cell Cardiol 2010, 48:45-54.
4. ATP channels: recent insights to energy sensing and myoprotection. Physiol Rev 2010, 90:799-829.
5. IR2.x inward rectifier ion channel family: expression patterns and pathophysiology. Acta Physiol 2010, 199:243-255.
6. +-channel proteins. Nature 1995, 374:135-141.
7. KATP: An inward rectifier subunit pulus the sulfonylurea receptor. Science 1995, 270:1166-1170.
8. Dean M, Annilo T Evolution of the ATP-Binding Cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genom Hum Genet 2005, 6:123-142.
9. IR2.2 genes. J Physiol 2001, 533:697-710.
10. IR2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001, 105:511-519.
11. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005, 96:800-807.
12. Vega AL, Tester DJ, Ackerman MJ, et al. Protein kinase A-dependent biophysical phenotype for V227F-KCNJ2 mutation in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2009, 2:540-547.
13. IR2.1 currents. Cardiovasc Res 2012, 93:666-673.
14. KACh. J Biol Chem 2002, 277:48282-48288.
15. Wickman K, Nemec J, Gendler SJ, et al. Abnormal heart rate regulation in GIRK4 knockout mice. Neuron 1998, 20:103-114.
16. IR3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010, 86:872-880.
17. IR6.1. Nat Med 2002, 8:466-472.
18. IR6.2-null mice. Am J Physiol Heart Circ Physiol 2005, 288:352-357.
19. + channel, predisposes to catecholamine-induced ventricular dysrhythmia. Diabetes 2004, 53:S165-S168.
20. ATP channels require SUR1. Circ Res 2008, 103:1458-1465.
21. Elrod JW, Harrell M, Flagg TP, et al. Role of sulfonylurea receptor type 1 subunits of ATP-sensitive potassium channels in myocardial ischemia/reperfusion injury. Circulation 2008, 117:1405-1413.
22. Stoller D, Kakkar R, Smelley M, et al. Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress. J Mol Cell Cardiol 2007, 43:445-454.
23. ATP channel. J Cardiovasc Electrophysiol 2009, 20:93-98.
24. IR6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010, 7:1466-1471.
25. Barajas-Martínez H, Hu D, Ferrer T, et al. Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm 2012, 9:548-555.
26. Delaney JT, Muhammad R, Blair MA, et al. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. Europace 2012.
27. ATP channel and sudden infant death syndrome. Circ Cardiovasc Genet 2011, 4:510-515.
28. ATP channel gating. Nat Genet 2004, 36:382-387.
29. ATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med 2007, 4:110-116.
30. Harakalova M, van Harssel JJ, Terhal PA, et al. Dominant missense mutations in ABCC9 cause Cantú syndrome. Nat Genet 2012, 44:793-796.
31. Noujaim SF, Stuckey JA, Ponce-Balbuena D, et al. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J 2012, 4:4302-4312.
32. Tamargo J, Caballero R, Gómez R, et al. Pharmacology of cardiac potassium channels. Cardiovasc Res 2004, 62:9-33.
33. + channel by gambogic acid. J Biol Chem 2009, 284:15432-15438.
34. Brown JH, Laiken N Muscarinic receptors agonists and antagonists. Goodman and Gilman's The Pharmacological Basis of Therapeutics 2011, McGraw-Hill. ed 12, New York. L. Brunton, B. Chabner, B. Knollman (Eds.).
35. Dobrev D, Carlsson L, Nattel S Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 2012, 11:275-291.
36. McBride BF The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation. J Clin Pharmacol 2009, 49:258-267.
37. K1 modulators for in vivo application; old drugs point the way. Hearth Rhythm 2011, 8:1076-1080.
38. Sanchez-Chapula JA, Salinas-Stefanon E, Torres-Jacome J, et al. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharm Exp Ther 2001, 297:437-445.
39. IR2.1 channel. Proc Natl Acad Sci U S A 2008, 105:1364-1368.
40. IR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel. Br J Pharmacol 2010, 159:1532-1541.
41. Noujaim SF, Stuckey JA, Ponce-Balbuena D, et al. Structural bases for the different antifibrillatory effects of chloroquine and quinidine. Cardiovasc Res 2011, 89:1-8.
42. IR2.1 channels responsible for variant 3 short qt syndrome. J Mol Cel Cardiol 2009, 47:743-747.
43. IR2.1 channel responsible for short QT syndrome and normalizes repolarization properties in silico. Cell Physiol Biochem 2009, 24:153-160.
44. Fan Z, Makielski JC Anionic phospholipids activate ATP-sensitive potassium channels. J Biol Chem 1997, 272:5388-5395.
45. 2 with ion channels and transporters. Sci STKE 2001, RE19.
46. IR channels by diverse modulators. J Biol Chem 2004, 279:37271-37281.
47. + channels. Pflugers Arch 2007, 455:83-95.
48. IR2.2. Nature 2011, 477:495-498.
49. Lundbæk JA Lipid bilayer-mediated regulation of ion channel function by amphiphilic drugs. J Gen Physiol 2008, 131:421-429.
50. + channels. Proc Natl Acad Sci U S A 2001, 98:6482-6487.
51. IR2.x family of inward rectifier channels by interfering with PIP2-channel intaractions. J Pharm Exp Ther 2009, 331:563-573.
52. 2-channel interaction. J Pharm Sci 2010, 113:66-75.
53. 2 -channel interaction. J Cardiovasc Pharmacol 2011, 57:407-415.
54. 2-channel interaction. Eur J Pharmacol 2011, 668:72-77.
55. IR6.2 channels. Pflügers Arch 2011, 462:505-517.
56. IR currents by antihistamines. Eur J Pharmacol 2007, 558:21-26.
57. López-Izquierdo A, Ponce-Balbuena D, Ferrer T, et al. Thiopental inhibits function of different inward rectifying potassium channel isoforms by a similar mechanism. Eur J Pharmacol 2010, 638:33-41.
58. IR2.1 currents by interacting with Cysteine 311 decreasing the polyamine-induced rectification. Proc Nat Acad Sci U S A 2010, 107:15631-15636.
59. IR2.3. PLoS One 2009, 4:e6311.